Mahamaya Lifesciences Limited has uploaded its investor presentation to its corporate website, providing stakeholders with detailed insights ahead of the scheduled virtual investor and analyst meeting on August 07, 2026. The company disclosed the availability of the presentation on August 07, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This proactive disclosure aims to equip investors with comprehensive information regarding the company’s operations, strategy, and financial performance before the interactive session.

The virtual meeting is scheduled to commence at 4:00 PM IST on Friday, August 07, 2026. Mahamaya Lifesciences explicitly stated that the presentation and the subsequent discussion will not contain any unpublished price-sensitive information (UPSI). All interactions will be based strictly on publicly available data, ensuring adherence to regulatory standards for fair disclosure. The meeting will be conducted via video conferencing as a group session, allowing broad participation from investors and analysts.

Meeting Details

Management Speakers

Senior leadership from Mahamaya Lifesciences will lead the discussion:

• Krishnamurthy Ganesan, Managing Director
• Prashant Krishnamurthy, Executive Director & CFO

Investors and analysts can register for the meeting through the provided QR code or via the Orim Connect platform. The company noted that the meeting may be cancelled, rescheduled, or postponed due to exigencies involving the analysts, investors, or company management.

Regulatory Compliance

Pursuant to Regulation 46(2) of the Listing Regulations, the intimation regarding the investor meet and the associated presentation has been uploaded to the company’s website at www.mahamayalifesciences.com . The disclosure was submitted to the Listing Compliance Department of BSE Limited, where the company is listed under Scrip Code 544611 on the BSE SME platform. The presentation serves as a supplementary document to the earlier schedule announcement made on August 04, 2026.

What This Means for Investors

The release of the investor presentation allows stakeholders to review the company’s strategic direction and operational metrics in detail before engaging with management. By restricting discussions to public data, Mahamaya Lifesciences maintains transparency while adhering to SEBI guidelines. Participants should prepare questions focused on publicly reported financials and operational updates.

Mahamaya Lifesciences has accepted the resignation of Shilpi Bhardwaj as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). The departure is effective July 30, 2026, with Bhardwaj citing alternate career opportunities outside the organization as the reason for her exit. The company confirmed that there are no material reasons for her resignation other than those stated.

The Board of Directors approved the resignation on July 30, 2026. Bhardwaj submitted her resignation letter dated June 10, 2026, under the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Companies Act, 2013. She will be relieved from her duties at the close of business hours on July 30, 2026.

Resignation Details

Bhardwaj confirmed in her resignation letter that she would extend all necessary assistance and cooperation to ensure a smooth handover of responsibilities during the notice period. The company disclosed the change pursuant to Regulation 30 read with Paragraph A, Part A of Schedule III of the SEBI Listing Regulations, 2015.

Krishnamurthy Ganesan, Managing Director of Mahamaya Lifesciences, signed the intimation to BSE Limited. The filing included Annexure A detailing the event and the resignation letter. No other material changes in key managerial personnel were reported alongside this announcement.